Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | BCR | P11274 | 1/20 | 0.52 |
| ▸ | AXL | P30530 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30772298 | 1.00 | TGFBR1 (0.60) | TGFBR1TSHRKDM4EPOLBMAPT | |
| SCHEMBL31039975 | 0.88 | TGFBR1 (0.56) | TGFBR1TSHRKDM4EPOLBMAPT | |
| SCHEMBL14642565 | 0.87 | TRPV1 (0.50) | TGFBR1TSHRKDM4EPOLBMAPT | |
| SCHEMBL989567 | 0.85 | AXL (0.56) | TGFBR1TSHRKDM4EPOLBMAPT | |
| SCHEMBL5562975 | 0.85 | GRM5 (0.64) | TGFBR1TSHRKDM4EABL1BCR | |
| SCHEMBL475480 | 0.85 | AXL (0.56) | TGFBR1TSHRKDM4EPOLBMAPT | |
| SCHEMBL10020883 | 0.85 | KDM4E (0.57) | TGFBR1TSHRKDM4EPOLBMAPT | |
| SCHEMBL28354219 | 0.84 | TGFBR1 (0.53) | TGFBR1TSHRKDM4EPOLBMAPT | |
| SCHEMBL1303881 | 0.84 | TGFBR1 (0.53) | TGFBR1TSHRKDM4EPOLBMAPT | |
| SCHEMBL1302416 | 0.83 | ALDH1A1 (0.51) | TGFBR1TSHRKDM4EPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024126392-A1 | VECTORIZED NHC IRIDIUM(III) COMPLEXES AND USE THEREOF IN PHOTODYNAMIC THERAPY AND/OR DIAGNOSTIC | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-06-20 | — | — | WO | claimed |
| EP-4385995-A1 | VECTORIZED NHC IRIDIUM(III) COMPLEXES AND USE THEREOF IN PHOTODYNAMIC THERAPY AND/OR DIAGNOSTIC | Centre National de la Recherche Scientifique (FR) | 2024-06-19 | — | — | EP | claimed |
| EP-1093367-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | claimed |
| EP-1093367-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-25 | — | — | EP | claimed |
| WO-1999066925-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-29 | — | — | WO | claimed |
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| EP-4559902-A2 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3256218-B1 | A KDM1A INHIBITOR AND ITS USE IN THERAPY | IMAGO BIOSCIENCES INC (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2024126392-A1 | VECTORIZED NHC IRIDIUM(III) COMPLEXES AND USE THEREOF IN PHOTODYNAMIC THERAPY AND/OR DIAGNOSTIC | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024126392-A1 | VECTORIZED NHC IRIDIUM(III) COMPLEXES AND USE THEREOF IN PHOTODYNAMIC THERAPY AND/OR DIAGNOSTIC | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-06-20 | — | — | WO | disclosed |
| EP-4385995-A1 | VECTORIZED NHC IRIDIUM(III) COMPLEXES AND USE THEREOF IN PHOTODYNAMIC THERAPY AND/OR DIAGNOSTIC | Centre National de la Recherche Scientifique (FR) | 2024-06-19 | — | — | EP | disclosed |
| CN-117430549-A | Method for preparing isonicotinic acid compound by taking carbon dioxide as carboxyl source | 南开大学 | 2024-01-23 | — | — | CN | disclosed |
| US-6110946-A | AN ENZYME INHIBITORS OF RETROVIRAL ASPARTATE PROTEASE FOR THE TREATMENT OF AIDS | NOVARTIS FINANCE CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| WO-1999066925-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5912352-A | CATALYTIC REDUCTION OF HYDRAZIDE TO HYDRAZINE DERIVATIVE IN PRESENCE OF COMPLEX HYDRIDE; ACYL MIGRATION; HYDROGENATION; CATALYST SELECTIVITY | NOVARTIS FINANCE CORPORATION (US) | 1999-06-15 | — | — | US | disclosed |
| CN-1216539-A | Heterocyclic azahexane derivatives with antiviral activity | NOVARTIS AG (CH) | 1999-05-12 | — | — | CN | disclosed |
| EP-0900210-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | Novartis AG (CH) | 1999-03-10 | — | — | EP | disclosed |
| US-5849911-A | Antivirally active heterocyclic azahexane derivatives | NOVARTIS FINANCE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
| WO-1997046514-A1 | PROCESS FOR THE PREPARATION OF HYDRAZINE DERIVATIVES USEFUL AS INTERMEDIATES FOR THE PREPARATION OF PEPTIDE ANALOGUES | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997040029-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | CBR1, CNR1, CBR3 | TGFBR1 1623/4885TSHR 98/4885KDM4E 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.